Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo.

Chen CH, Chen MC, Wang JC, Tsai AC, Chen CS, Liou JP, Pan SL, Teng CM.

Clin Cancer Res. 2014 Mar 1;20(5):1274-87. doi: 10.1158/1078-0432.CCR-12-3909. Epub 2014 Feb 11.

PMID:
24520095
[PubMed - in process]
2.

Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.

Ou DL, Shen YC, Liang JD, Liou JY, Yu SL, Fan HH, Wang DS, Lu YS, Hsu C, Cheng AL.

Clin Cancer Res. 2009 Sep 15;15(18):5820-8. doi: 10.1158/1078-0432.CCR-08-3294. Epub 2009 Sep 8.

PMID:
19737956
[PubMed - indexed for MEDLINE]
Free Article
3.

The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells.

Chen MC, Chen CH, Wang JC, Tsai AC, Liou JP, Pan SL, Teng CM.

Cell Death Dis. 2013 Sep 19;4:e810. doi: 10.1038/cddis.2013.330.

PMID:
24052078
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Anticancer activity of MPT0E028, a novel potent histone deacetylase inhibitor, in human colorectal cancer HCT116 cells in vitro and in vivo.

Huang HL, Lee HY, Tsai AC, Peng CY, Lai MJ, Wang JC, Pan SL, Teng CM, Liou JP.

PLoS One. 2012;7(8):e43645. doi: 10.1371/journal.pone.0043645. Epub 2012 Aug 22. Erratum in: PLoS One. 2012;7(9). doi: 10.1371/annotation/ab4fff87-6a32-4718-aa4c-91658f164b8d. Huang, Han-Lin [corrected to Huang, Han-Li].

PMID:
22928010
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C.

Cancer Res. 2006 Dec 15;66(24):11851-8.

PMID:
17178882
[PubMed - indexed for MEDLINE]
Free Article
6.

Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma.

Deng L, Ren Z, Jia Q, Wu W, Shen H, Wang Y.

BMC Cancer. 2013 Jul 29;13:363. doi: 10.1186/1471-2407-13-363.

PMID:
23895220
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Novel combination of cyclooxygenase-2 and MEK inhibitors in human hepatocellular carcinoma provides a synergistic increase in apoptosis.

Schmidt CM, Wang Y, Wiesenauer C.

J Gastrointest Surg. 2003 Dec;7(8):1024-33.

PMID:
14675712
[PubMed - indexed for MEDLINE]
8.

Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.

Chen KF, Chen HL, Shiau CW, Liu CY, Chu PY, Tai WT, Ichikawa K, Chen PJ, Cheng AL.

Br J Pharmacol. 2013 Feb;168(3):658-72. doi: 10.1111/j.1476-5381.2012.02212.x.

PMID:
22978563
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y, Villanueva A, Minguez B, Tsai HW, Ward SC, Thung S, Friedman SL, Llovet JM.

J Hepatol. 2012 Jun;56(6):1343-50. doi: 10.1016/j.jhep.2012.01.009. Epub 2012 Feb 6.

PMID:
22322234
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.

Dai XF, Ding J, Zhang RG, Ren JH, Ma CM, Wu G.

Int J Radiat Biol. 2013 Sep;89(9):724-31. doi: 10.3109/09553002.2013.791405. Epub 2013 May 31.

PMID:
23682582
[PubMed - indexed for MEDLINE]
11.

Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.

Katz SI, Zhou L, Chao G, Smith CD, Ferrara T, Wang W, Dicker DT, El-Deiry WS.

Cancer Biol Ther. 2009 Dec;8(24):2406-16. Epub 2009 Dec 2.

PMID:
20038816
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Sorafenib enhances radiation-induced apoptosis in hepatocellular carcinoma by inhibiting STAT3.

Huang CY, Lin CS, Tai WT, Hsieh CY, Shiau CW, Cheng AL, Chen KF.

Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):456-62. doi: 10.1016/j.ijrobp.2013.01.025. Epub 2013 Mar 6.

PMID:
23474115
[PubMed - indexed for MEDLINE]
13.

Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models.

Shieh JM, Wei TT, Tang YA, Huang SM, Wen WL, Chen MY, Cheng HC, Salunke SB, Chen CS, Lin P, Chen CT, Wang YC.

PLoS One. 2012;7(1):e30240. doi: 10.1371/journal.pone.0030240. Epub 2012 Jan 18.

PMID:
22279574
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways.

Wei G, Wang M, Carr BI.

J Cell Physiol. 2010 Jul;224(1):112-9. doi: 10.1002/jcp.22099.

PMID:
20301194
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation.

Dasmahapatra G, Yerram N, Dai Y, Dent P, Grant S.

Clin Cancer Res. 2007 Jul 15;13(14):4280-90.

PMID:
17634558
[PubMed - indexed for MEDLINE]
Free Article
16.

Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.

Manov I, Pollak Y, Broneshter R, Iancu TC.

FEBS J. 2011 Sep;278(18):3494-507. doi: 10.1111/j.1742-4658.2011.08271.x.

PMID:
21790999
[PubMed - indexed for MEDLINE]
17.

Histone deacetylase inhibitors enhance the apoptotic activity of insulin-like growth factor binding protein-3 by blocking PKC-induced IGFBP-3 degradation.

Oh SH, Whang YM, Min HY, Han SH, Kang JH, Song KH, Glisson BS, Kim YH, Lee HY.

Int J Cancer. 2012 Nov 15;131(10):2253-63. doi: 10.1002/ijc.27509. Epub 2012 Mar 28.

PMID:
22362554
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells.

Tai WT, Shiau CW, Chen HL, Liu CY, Lin CS, Cheng AL, Chen PJ, Chen KF.

Cell Death Dis. 2013 Feb 7;4:e485. doi: 10.1038/cddis.2013.18.

PMID:
23392173
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines.

Pasqualetti G, Ricciardi S, Mey V, Del Tacca M, Danesi R.

Lung Cancer. 2011 Nov;74(2):197-205. doi: 10.1016/j.lungcan.2011.03.003. Epub 2011 May 6.

PMID:
21529991
[PubMed - indexed for MEDLINE]
20.

Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.

Chen KF, Yu HC, Liu TH, Lee SS, Chen PJ, Cheng AL.

J Hepatol. 2010 Jan;52(1):88-95. doi: 10.1016/j.jhep.2009.10.011. Epub 2009 Oct 23.

PMID:
19913321
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk